159.43
-0.24%
Close of 19 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $30.82bn
- Last close × shares
- Volume
- 3.4m
- Shares, 19 Nov 2026
About Revolution Medicines
From its filings with the US Securities and Exchange Commission
Revolution Medicines is based in Redwood City, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker RVMD. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $1.13bn. At that date it held total assets of $2.35bn and shareholders' equity of $1.63bn.
We are a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. We possess sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Guided by our understanding of genetic drivers and adaptive resistance mechanisms in cancer, we deploy precision medicine approaches to inform innovative monotherapy and combination regimens. Our research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors) that are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
We believe tailored RAS(ON) Inhibitors will be useful to serve the diverse landscape of RAS-addicted cancers optimally. In some cases, patients may experience maximal clinical benefit from the broad activity of a RAS(ON) multi-selective inhibitor, such as daraxonrasib (RMC-6236), which is designed to inhibit multiple oncogenic RAS variants. In other settings, treatment with a RAS(ON) mutant-selective inhibitor, designed to selectively target a specific RAS mutation, may be optimal. We further believe that in some cases, it could be beneficial to combine daraxonrasib with a RAS(ON) mutant-selective inhibitor, with daraxonrasib functioning as the backbone of these RAS(ON) Inhibitor doublets.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
How it makes its money
Revenue, year to 31 Dec 2022
- Collaboration revenue member. $35.4m · 100.0%
Latest on Revolution Medicines
Our reporting
- Revolution Medicines falls 2.50% in Tuesday's session
- Revolution Medicines falls 3.15% in Monday's session
- Revolution Medicines falls 2.30% in Friday's session
- Revolution Medicines falls 2.41% in Thursday's session
- Revolution Medicines falls 6.40% in Wednesday's session
- Revolution Medicines falls 3.54% in Tuesday's session
Next results
Due on 24 Feb 2027. Analysts expect earnings of -1.16 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is Revolution Medicines's ticker?
Revolution Medicines trades as RVMD on its US listing, under ISIN US76155X1000.
What was Revolution Medicines's last closing price?
159.43 on 19 Nov 2026. The figure is in USD and is never converted.
When does Revolution Medicines next report results?
Results are expected on 24 Feb 2027, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.